Epilepsy

William Rosenfeld, MD, discusses the decreases his team observed in concomitant medication use with cenobamate in patients with focal seizures.

The CEO of Nile AI spoke to how the newly founded company plans to develop data science techniques to improve the optimization of epilepsy care and management.

The clinical fellow at Massachusetts General Hospital detailed his research on neurology resident EEG education, and the increased need for more consistency throughout programs.

Brain Scientific’s disposable EEG cap can be applied by any clinical staff member within 5 minutes.

The percentage of women who had ≥1 change in an antiepileptic drug dose or an overall dose increase during pregnancy and a decrease in dose during the postpartum period was higher among pregnant women than controls.

Here's what is coming soon to NeurologyLive.

The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to catch refractory epilepsy early and look for the most efficacious treatments for their patients.

Although the percentage of total seizures arising from REM was low, it is notable that 2 out of 26 patients (7.7%) had REM-onset seizures.

Neurology News Network for the week ending January 9, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 8, 2021.

The investigation identified 13 novel and significant associations with cerebrovascular disease and transient cerebral ischemia.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team saw a roughly 25% decrease in the mean use of concomitant ASMs.

The GW Pharmaceuticals product resulted in nearly 50% reductions in seizures at both 25 mg/kg and 50 mg/kg dose groups.

Neuronaute consists of a smart shirt and smart cap containing biosensors that monitor physiological characteristics, such as muscle activity and heart and respiratory rate.

A recent analysis of UnitedHealthcare insurance claims revealed increases of almost 200% for some services between 2001 and 2016.

The agent will aim to be the first and only FDA-approved liquid formulation of topiramate, with a PDUFA date set in Q3 of 2021.

Here's what is coming soon to NeurologyLive.